[Immunopharmacological actions of lumin (II): Effect of lumin administration in NZB X NZW (B/W) F1 mice].
Lumin was administered at doses of 0.1 to 100 micrograms/kg for 5 months to NZB/W F1 mice as the model animal for studying systemic lupus erythematosus (SLE), a human autoimmune disease. The increase in anti-thymic autoantibody level was significantly inhibited at doses of 1 to 100 micrograms/kg. Also, the induction of suppressor T cells by concanavalin A was significantly promoted. In addition, recovery activity was significantly observed, over-coming the reduction in plaque-forming cell (PFC) response of anti-sheep erythrocytes at a dose of 100 micrograms/kg, as well as the reduction in PFC response of anti-trinitrophenylated-lipopolysaccharide at doses of 0.1 to 100 micrograms/kg. The above results prove that lumin exhibits an immunomodulating effect against immune disease in mice.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D005260:Female; D006824:Hybridization, Genetic; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007518:Isoantibodies / Q000096:biosynthesis; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D011806:Quinolinium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011806:Quinolinium Compounds; C035678:anti-Thy antibody; C052194:lumin